ArticleProceedings of the National Academy of Sciences of the United States of America1998
In vitro loss of heterozygosity targets the PTEN/MMAC1 gene in melanoma.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 97 citations in OpenAlex.
- Phenotypic and Dermoscopic Patterns of Familial Melanocytic Lesions: A Pilot Study in a Third-Level Center.Cancers · 2023Article
- ROR2 has a protective role in melanoma by inhibiting Akt activity, cell-cycle progression, and proliferation.Journal of biomedical science · 2021Article
- Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications.Frontiers in molecular biosciences · 2020Review
- Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma.Proceedings of the National Academy of Sciences of the United States of America · 2016Article
- Current State of Animal (Mouse) Modeling in Melanoma Research.Cancer growth and metastasis · 2015Review
- Chromosome 10, frequently lost in human melanoma, encodes multiple tumor-suppressive functions.Cancer research · 2014Article
- Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma.Pigment cell & melanoma research · 2013Article
- Loss of SHIP-1 protein expression in high-risk myelodysplastic syndromes is associated with miR-210 and miR-155.Oncogene · 2012Article
- Melanoma: from mutations to medicine.Genes & development · 2012Review
- Genetic alterations of PTEN in human melanoma.Cellular and molecular life sciences : CMLS · 2012Review
- Therapeutic Implications of Targeting AKT Signaling in Melanoma.Enzyme research · 2011Article
- α-Mannosidase 2C1 attenuates PTEN function in prostate cancer cells.Nature communications · 2011Article
- Analysis of the genome to personalize therapy for melanoma.Oncogene · 2010Review
- KLF6 Gene and early melanoma development in a collagen I-rich extracellular environment.Journal of the National Cancer Institute · 2010Article
- Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.The Journal of clinical investigation · 2010Article
- Oncogenic mutations of PIK3CA in human cancers.Current topics in microbiology and immunology · 2010Review
- The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma.Pigment cell & melanoma research · 2009Review
- Genetics and genomics of melanoma.Expert review of dermatology · 2009Article
- BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma.Pigment cell & melanoma research · 2009Article
- Growth factors and oncogenes as targets in melanoma: lost in translation?Advances in dermatology · 2007Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Gross genetic lesions of chromosome 10 occur in 30-50% of sporadic human melanomas. To test the functional significance of this observation, we have developed an in vitro loss of heterozygosity approach in which a wild-type chromosome 10 was transferred into melanoma cells, where there was selection for its breakage and regional deletion to relieve its growth suppressive effects. The overlap of these events was at band 10q23, the site of the recently isolated PTEN/MMAC1 tumor suppressor gene, suggesting it as a potential target. Although the gene was expressed in the parental cells, both of its chromosomal alleles contained truncating mutations. In vitro loss of heterozygosity resulted in loss of the chromosomally introduced wild-type PTEN/MMAC1, and ectopic expression of the gene caused cell growth suppression. Thus, this approach identified PTEN/MMAC1 as a target in malignant melanoma and may provide an alternative means to localizing tumor suppressor genes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.